Isoxazole Hydroxamic Acids for Selective HDAC6 Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current HDAC inhibitors lack isoform selectivity, particularly for HDAC6, which is a promising therapeutic target for treating diseases such as cancer and certain CNS disorders, necessitating the development of new agents that can selectively inhibit this enzyme.

Innovation Solution

Development of isoxazole-substituted hydroxamic acid compounds that act as selective HDAC6 inhibitors, providing therapeutic benefits for conditions like cancer, neurological diseases, and autoimmune disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If pan-selective HDAC inhibitors are used, then broad HDAC enzyme inhibition is achieved, but isoform selectivity is lost

Engineering Contradiction:

Improvebroad HDAC inhibitionVSAvoidisoform selectivity

Core Design Contradiction:

Adaptability or versatilityVSMeasurement precision

Solution Approach 1:

The patent applies local quality by designing the hydroxamic acid inhibitor with specific molecular features (isoxazole substitution patterns, particular R-group configurations) that create localized interaction preferences for HDAC6's active site. This allows the compound to maintain broad HDAC inhibition capability while introducing selective binding characteristics through specific structural modifications at key positions.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by systematically varying molecular parameters of the hydroxamic acid core structure, including substitution patterns on the isoxazole ring, chain length variations, and functional group modifications. These parameter adjustments fine-tune the inhibitor's affinity and selectivity profile across different HDAC isoforms, particularly enhancing HDAC6 preference.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing HDAC inhibitors are developed, then cancer therapy benefits are provided, but therapeutic specificity for HDAC6 is insufficient

Engineering Contradiction:

Improvecancer therapy efficacyVSAvoidHDAC6 target specificity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies segmentation by dividing the HDAC inhibitor design into distinct functional modules: a hydroxamic acid warhead for zinc coordination, an isoxazole-substituted aromatic core for hydrophobic interactions, and tunable linker regions for optimizing binding geometry. This modular approach enables independent optimization of each segment to achieve both efficacy and HDAC6 specificity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent uses the isoxazole-substituted hydroxamic acid structure as an intermediary that mediates selective interaction between the inhibitor and HDAC6's active site. This intermediary structure facilitates specific hydrogen bonding, hydrophobic packing, and zinc coordination that preferentially engages HDAC6 while maintaining inhibition of other HDAC isoforms.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12522572B2Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors

Publication Date: 2026.01.13 GEORGE WASHINGTON UNIVERSITY

AI summary

The present disclosure provides compounds represented by Formula I:and pharmaceutically acceptable salts, solvates, e.g., hydrates, and prodrugs thereof, wherein X and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat diseases and conditions, e.g., cancer, wherein inhibition of HDAC provides a benefit.